GleamWall
中文EN

IBO IMPACT BIOMEDICAL INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1834105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY103.7%
TTM EPS YoY184.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,655.3%
Net margin4,247.4%
FCF margin—
EBITDA margin-9,657.9%

Returns

ROE—
ROA9.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.00x
Current ratio0.04x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio8.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$32,000—
Cost of revenue$424,000—
Gross profit-$392,000—
R&D expense$340,000$278,000
SG&A expense$873,000$718,000
Operating income-$4.28M-$28.75M
Interest expense$793,000$1.06M
Pretax income-$14.45M-$24.74M
Income tax-$2.58M$33,000
Net income-$11.84M-$24.71M
EBITDA-$3.14M-$27.63M
EPS (basic)-0.38-2.30
EPS (diluted)-0.38-2.30
Balance sheet
Cash & equivalents$3,000$2.00M
Receivables$5,000$201,000
Inventory$63,000—
Current assets$411,000$2.45M
PP&E, net—$17,000
Goodwill—$25.09M
Intangibles$16.99M$17.81M
Total assets$17.41M$20.29M
Current liabilities$1.16M$9.79M
Total liabilities$1.85M$13.05M
Shareholders' equity$12.31M$4.26M
Shares outstanding8.29M11.50M
Cash flow statement
Operating cash flow-$1.89M-$2.85M
Investing cash flow$3,000$2,000
Financing cash flow-$109,000$4.85M
Depreciation & amortization$1.15M$1.12M
Stock-based compensation$13,000$19,000

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.